Dec 13, 2024 | Blog, News, Skeletal Diseases and Injuries, Stem Cell News, Stem Cell Therapies
England flanker Tom Curry is undergoing stem cell therapy as a follow-up to last year’s career-saving surgery.[1] Suffering from chronic hip pain and reduced range of motion, Curry was diagnosed with femoroacetabular impingement syndrome, where the ball of the hip...
Nov 15, 2024 | Blog, News, Stem Cell News, Uses for Cord Blood
Today marks World Cord Blood Day—a day dedicated to highlighting the medical breakthrough that began 36 years ago, in 1988, with a single transplant. That cord blood transplant opened the door to a new era in medicine. Since then, stem cells from cord blood have...
Nov 11, 2024 | Blog, Eye Conditions, News, Stem Cell News, Stem Cell Therapies, Uses for Cord Blood
A recent study published in the Lancet journal has shown that stem cells have been used to bring about significant improvements in vision in what’s being heralded as a world first. The stem cell treatment focused on the repair of the cornea which becomes damaged in...
Nov 1, 2024 | Blog, News, Uses for Placenta
A recent story published by The New York Times has highlighted the life-changing potential placenta holds for the treatment of severe burns and wounds. The story follows Marcella Townsend, who was left unrecognisable by second and third degree burns she suffered after...
Aug 21, 2024 | Blog, Heart and Vascular Disease, News, Stem Cell News, Stem Cell Therapies
A new clinical trial investigating the use of umbilical cord stem cells to treat chronic heart failure is currently underway. The Phase II trial, which is the first of its kind in the U.S., is being carried out by researchers at the University of Louisville. It’s also...
Aug 14, 2024 | Blog, Blood Disorders, News, Stem Cell News, Stem Cell Therapies
Last week it was announced that a new gene editing stem cell therapy for beta thalassemia would start to be made available on the NHS. The therapy, called Casgevy, is developed by Vertex Pharmaceuticals and CRISPR Therapeutics and received approval from the UK...